Literature DB >> 17715273

Epilepsy in children in Navarre, Spain: epileptic seizure types and epileptic syndromes.

Teodoro Durá-Travé1, María Eugenia Yoldi-Petri, Fidel Gallinas-Victoriano.   

Abstract

Data for children 1 month to 15 years of age at the time of diagnosis of epilepsy were recorded from the children's hospital "Virgen del Camino" in Pamplona (Spain) from January to December 2005. International League Against Epilepsy criteria were used for diagnoses. A total of 365 children were recruited into the study. Mean age at diagnosis was 5.97 years, and time of follow-up was 4.6 years. Etiology was idiopathic in 166 (45.5%), cryptogenic in 106 (29.0%), and symptomatic in 93 (25.5%). Focal seizures were seen in 52.9% of the patients, generalized epilepsy in 43.5%, and 3.6% were not determined. In infants, West syndrome (34.1%) and focal symptomatic seizures (24.4%) were the most prevalent syndromes. In early childhood, the main syndromes were cryptogenic focal epilepsies (17.7%) and Doose syndrome (12.8%). In school-aged children, benign epilepsies (27.3%) and absences (24.5%) were prevalent. In adolescents, cryptogenic focal epilepsies (26.6%) and benign epilepsies (23.4%).

Entities:  

Mesh:

Year:  2007        PMID: 17715273     DOI: 10.1177/0883073807304207

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  3 in total

1.  Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis.

Authors:  Jesse Elliott; Bláthnaid McCoy; Tammy Clifford; George A Wells; Doug Coyle
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

2.  Clinical profile and treatment outcome of epilepsy syndromes in children: A hospital-based study in Eastern Nepal.

Authors:  Prakash Poudel; Shyam Prasad Kafle; Rita Pokharel
Journal:  Epilepsia Open       Date:  2021-02-08

3.  Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials.

Authors:  Jennifer Madan Cohen; Daniel Checketts; Eduardo Dunayevich; Boudewijn Gunning; Ann Hyslop; Deepak Madhavan; Vicente Villanueva; Marta Zolnowska; Sameer M Zuberi
Journal:  Epilepsia       Date:  2021-07-15       Impact factor: 5.864

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.